This is a global information resource. It is intended for healthcare professionals outside of the United States of America who are interested in information about ALECENSA. If you are a United States of America healthcare professional please click here.
The European Medicines Agency has approved ALECENSA monotherapy as:1
- Adjuvant treatment following complete tumour resection for adult patients with ALK+ NSCLC at high risk of recurrence
- First-line treatment of adult patients with ALK+ advanced NSCLC
- Treatment of adult patients with ALK+ advanced NSCLC previously treated with crizotinib
The registration status and approved product label of ALECENSA may not be the same in different countries. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Summary of Product Characteristics for full details.
This website has been updated according to the latest European Medicines Agency approval in June 2024.
